Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiamine Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TKT | P29401 | 11/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamine Ion SCHEMBL1704948 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL23290122 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL193755 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL5520463 | 0.99 | HSP90AA1 (0.98) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL28524160 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL5317564 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL1251742 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL30028012 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL7200449 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA | |
| Thiamine Ion SCHEMBL10534682 | 0.98 | HSP90AA1 (0.95) | HSP90AA1TDP1KDM4ETKTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118975991-A | Ticagrelor freeze-dried preparation as well as preparation method and application thereof | 江苏联环药业股份有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-116818924-A | Detection method of related substances in anticholinergic drug thiabendazole | 南京联智医药科技有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-121049418-A | Ticagrel ammonium bromide intermediate and normal phase chromatographic analysis and detection method of enantiomer thereof | 南京联智医药科技有限公司 | 2025-12-02 | — | — | CN | disclosed |
| US-12338244-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | UNIVERSITY OF MASSACHUSETTS (US) | 2025-06-24 | — | — | US | disclosed |
| CN-115792071-B | Analysis method for related substances of thiamine bromide intermediate | 南京联智医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115792071-B | Analysis method for related substances of thiamine bromide intermediate | 南京联智医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115792071-B | Analysis method for related substances of thiamine bromide intermediate | 南京联智医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118975991-A | Ticagrelor freeze-dried preparation as well as preparation method and application thereof | 江苏联环药业股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118975991-A | Ticagrelor freeze-dried preparation as well as preparation method and application thereof | 江苏联环药业股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240254127-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | UNIVERSITY OF MASSACHUSETTS | 2024-08-01 | — | — | US | disclosed |
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | UNIVERSITY OF MASSACHUSETTS (US) | 2024-02-27 | — | — | US | disclosed |
| CN-101603020-B | Growth medium c. histolyticum without ingredients of mamalian sources | HOFFMANN LA ROCHE | 2014-03-12 | — | — | CN | disclosed |
| US-8236356-B2 | Growth medium for Clostridium histolyticum | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| CN-102548548-A | Ophthalmic pharmaceutical composition for use in medicine and veterinary medicine | MITOTECH S A | 2012-07-04 | — | — | CN | disclosed |
| US-20120094962-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY | MITOTECH SA (LU) | 2012-04-19 | — | — | US | disclosed |
| EP-2441453-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY | Limited Liability Company Mitotech (RU) | 2012-04-18 | — | — | EP | disclosed |
| US-20100086971-A1 | GROWTH MEDIUM FOR CLOSTRIDIUM HISTOLYTICUM | ROCHE DIAGNOSTICS GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| EP-2133415-A1 | Growth medium for Clostridium histolyticum without ingredients of mammalian sources | Roche Diagnostics GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| CN-101603020-A | The clostridium histolyticum growth medium of no Mammals derived components | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| US-20070264352-A1 | Biostimulate and tonic solution for massage (solution \"Biplatvirs\") | BRILMAN YAKOV | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | HSP90AA1 439/4885TDP1 12/4885KDM4E 1278/4885 |
| US-20240254127-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | PBRM1, MGMT, TOP1 | HSP90AA1 439/4885TDP1 12/4885KDM4E 1278/4885 |
| US-12338244-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | HSP90AA1 439/4885TDP1 12/4885KDM4E 1278/4885 |
| US-20120094962-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY | MT-CO3, COX5B, COX6A1 | HSP90AA1 2593/4885TDP1 1337/4885KDM4E 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.